China's Sichuan to offer 25-day marriage leave, 150-day maternity leave
HONG KONG: Health authorities in China's southwestern Sichuan province are proposing to extend marriage leave up to 25 days and maternity leave up to 150 days, to help create a "fertility-friendly society" which boosts the country's population.
The move comes as China's government struggles to boost birth rates in the world's second-largest economy. China's population fell for a third consecutive year in 2024 and experts have cautioned the downturn will continue to worsen.
Sichuan's Health Commission, which published the draft on its website, is seeking public opinion and comments from May 30 to June 30. Sichuan province has a population of 84 million, more than most countries including Germany and the United Kingdom.
The proposal would extend marriage leave by 400 per cent from the five days currently given and more than double the existing 60-day maternity leave period.
Featured Videos
Sichuan also plans to extend paternity leave to 30 days from 20 days to "facilitate the care of men for their wives after childbirth and help advocate that couples share the responsibility of raising children," authorities said.
The province has emerged as one of the more progressive in China. It has allowed unmarried women to access IVF treatment and in 2023 authorities there announced that unmarried individuals would be eligible for benefits reserved for married couples.
China's birth rates have been falling for decades as a result of the one-child policy China implemented from 1980 to 2015 as well as rapid urbanisation.
The high cost of childcare and education as well as job uncertainty and a slowing economy have also discouraged many young Chinese from getting married and starting a family.
Authorities rolled out a series of "fertility friendly" measures in 2024 to minimise the challenge of having roughly 300 million Chinese expected to enter retirement in the coming decade - the equivalent of almost the entire US population.
Measures include urging China's colleges and universities to provide "love education" to emphasize positive views on marriage, love, fertility and family.
In November, China's State Council, or cabinet, rallied local governments to direct resources towards fixing China's population crisis and spread respect for childbearing and marriages "at the right age."
More than 2.6 million couples filed for divorce last year, the data showed, up 1.1 per cent from 2.59 million in 2023.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
a day ago
- The Sun
Hong Kong Baptist University Showcases World-Leading Research in Digital Health & Systems Medicine at THE Global Sustainable Development Congress 2025
ISTANBUL, TURKEY - Media OutReach Newswire - 19 June 2025 – Hong Kong Baptist University (HKBU) illuminated the path to global well-being as the Global Health Innovation Partner and sponsor of the Health and Wellbeing Track at the Times Higher Education (THE) Global Sustainable Development Congress (GSDC) 2025, from June 16-19, 2025. At this gathering of over 5,000 global thought leaders, HKBU presented its comprehensive, interdisciplinary strategy for health and well-being, spearheaded by its Health & Drug Discovery research cluster. Firmly aligned with the United Nations' Sustainable Development Goals, HKBU's vision for health transformation drives from data to actionable insight. It comprehensively integrates mental and digital well-being, real-time analytics, and innovative interdisciplinary approaches. This includes blending traditional Chinese Medicine with cutting-edge sciences like chemical biology and data analytics, complemented by advancements in environmental, physical, and social sciences. A Hub for Holistic Health A highlight of HKBU's presence was the 6,000-square-foot 'Well-being Zone', thoughtfully designed to embody the principle that health is holistic and interconnected. This innovative Zone brought the concept of interdisciplinarity to a global audience by seamlessly integrating diverse fields, from martial arts and mindfulness to cutting-edge digital health monitoring: • Interdisciplinary Movement & Mindfulness: Tai Chi, Baduanjin and Mindfulness Karate sessions demonstrated HKBU's 'exercise is medicine' philosophy. • Real-Time Digital Well-being Research: Participants had the unique opportunity to contribute live data for Professor Christy Cheung's pioneering studies, which explore how digital tools can effectively measure mindfulness and enhance overall well-being. • Expert-Led Talks: Distinguished HKBU academics presented cutting-edge interdisciplinary research. Topics included critical global health trends, advancements in mental well-being, and innovative applications of Chinese Medicine and AI in modern healthcare. • Reflection & Rejuvenation Spaces: Thoughtfully curated 'chill-out' relaxation areas, massage corners and a juice bar provided spaces for participants to experience a reboot of the body and the mind. Highlighting HKBU's research strength in the transformative power of technology for global health, Professor Martin Wong, Provost & Chair Professor of Computer Science, emphasised, 'HKBU's recent top-50 global ranking in databases, design automation, and artificial intelligence underscores our collaborative ethos. By integrating advanced AI methodologies with clinical, pharmaceutical and social-science expertise, we are optimising diagnostics, accelerating drug discovery and enhancing surgical assistance. This interdisciplinary approach reinforces Hong Kong's reputation as a global hub for cutting-edge research and higher education.' Professor Lyu Aiping, Vice-President (Research & Development), highlighted HKBU's strategic edge, 'Hong Kong is uniquely positioned to lead East–West integration in digital health and systems medicine. HKBU combines the rigour of life sciences with robust Chinese Medicine research, underpinned by advanced data analytics. This powerful synergy enables us to tackle complex health disparities at biological, social, and environmental levels, and build resilient, equitable health systems to meet future global challenges.' In addition to numerous insightful presentations and the interactive experiences, HKBU Provost Professor Martin Wong gave a keynote at the session entitled 'Reframing Sustainability through the Lens of Chinese Heritage and Innovation' convened by the China Education Association for International Exchange. HKBU also released the 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' Report ( in collaboration with Elsevier. This report examines the development and evolving research landscape of Chinese Medicine and its growing influence on modern healthcare.
New Straits Times
3 days ago
- New Straits Times
China pharma projects disrupted by Sino-US tensions
SHANGHAI: Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of US-China trade tensions. China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer and AstraZeneca with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work. Fears of delay in access to US supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources. They are also discussing testing US clinical samples in the US, instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said. The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains. All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously. US and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals. "What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou. He said the US-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding. Reliance on US imports has come into particular focus as trade tensions escalate. In 2024, the US exported diagnostic and laboratory reagents to China valued at about US$1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about US$125 million, U.N. Comtrade data showed. In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some US-made goods including diagnostic reagents from Germany's Siemens Healthineers were exempted from raised Chinese tariffs, that company said in May. China raised its tariffs on US imports to as much as 125 per cent though it has since reduced that to 10 per cent while it works out a more permanent trade deal. HIGHER COSTS, DELAYS WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch US-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said. The project had been temporarily paused during the discussions, which began prior to May, the source said. WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers." Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said. "If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said. Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary US-made culture medium from a US subsidiary of Japan's Fujifilm, a source at the Chinese firm said. The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said. A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China. STOCKPILING, US TESTING After China announced a large rise in tariffs for US imports in April, WuXi Biologics placed a bigger-than-normal order for reagents made in the US with a supplier because it was not sure how long that policy action would continue, said a source at the supplier. WuXi Biologics did not respond to requests for comment. Concerns about the potential for US export restrictions led China's Innovent Biologics and multinational BeOne Medicines to discuss with Massachusetts-headquartered Thermo Fisher Scientific the prospect of not sending US clinical samples to China, said a source at the US company. Testing US samples in-country instead of in China would be more expensive, the source said.
The Star
4 days ago
- The Star
Varsity students raise RM3,900 for hospital through plastic-free campaign
Chen (standing fifth from right) presenting the mock cheque to Prof Ewe (sixth from left) during the university's 40th convocation ceremony. A GROUP of graduates from Universiti Tunku Abdul Rahman's (UTAR) Public Relations programme donated close to RM4,000 to UTAR Hospital in Kampar. The 62 individuals raised RM3,858 through a corporate social responsibility (CSR) project called 'We Want No Plastic: We Are Fantastic Without Plastic'. Project director Chen Zhi Shan said a mock cheque presentation was held to hand over the funds to UTAR president Prof Datuk Dr Ewe Hong Tat was held during the university's 40th convocation ceremony. She said funds were raised through the sale of various items and community sponsorship. 'We sold fruits, yau char kwai (Chinese cruller), jelly, coffee and succulent plants. 'These items were packed in recyclable packaging or containers, which aligned with our campaign's goals,' she said, adding that it took about four months to raise the money. Chen said the group also sold merchandise such as tote bags and glass cups with glass straws to promote reusable items. 'The donation was also our way to give back to the community,' she said. The project, launched in June last year, was aimed at raising awareness of microplastic pollution, advocating for the reduction of single-use plastics as well as promoting healthier and more eco-friendly lifestyles. 'We were aware of the potential health risks posed by microplastics when preparing for this project, and this motivated us to make the project a reality. 'We hope that our efforts will not only impact the campus community but also raise broader awareness among the public,' said Chen. She said the group decided to donate the proceeds to the hospital as a gesture of gratitude. 'We want to give back to our alma mater and the community at large for their support in our academic journey. 'The donation supports the university's sustainability efforts and underscores its 'From Grads to Future Greats' message,' she added. In addition to expressing his gratitude for their contribution, Prof Ewe also congratulated the graduates on their achievement in securing UTAR's first-ever gold award in the Malaysia Public Relations Awards 2024 for their CSR project. ― By IVAN LOH
